<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00381004</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0267</org_study_id>
    <nct_id>NCT00381004</nct_id>
  </id_info>
  <brief_title>FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Fludarabine, Cyclophosphamide, and Rituximab (FCR) Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if using a combination of fludarabine,
      cyclophosphamide, and rituximab, with sargramostim (GM-CSF) can help to control previously
      untreated chronic lymphocytic leukemia (CLL). The safety of this combination will also be
      studied. This study will evaluate antibody-dependent cellular cytotoxicity (ADCC) and its
      relationship to response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fludarabine and cyclophosphamide are designed to enter CLL cells and destroy the &quot;machinery&quot;
      that allows CLL cells to multiply. Rituximab is designed to bind to CLL cells and cause cell
      death. GM-CSF is designed to help the bone marrow to produce white cells. It may also
      increase the target molecule called cluster of differentiation antigen 20 (CD20) for
      rituximab on the surface of the CLL cells which may improve the activity of rituximab.

      Before you can start treatment on this study, you will have what are called &quot;screening
      tests.&quot; These tests will help the doctor decide if you are eligible to take part in the
      study. You will have a complete physical exam. Blood (about 2 tablespoons) will be drawn for
      routine tests. The routine blood draw will include a test for hepatitis B, unless this has
      been done within the last 6 months. This routine blood draw will also include a pregnancy
      test for women who are able to have children. To be eligible to take part in this study, the
      pregnancy test must be negative. A bone marrow aspirate and biopsy will be collected. To
      collect a bone marrow aspirate and biopsy, an area of the hip or chest bone is numbed with
      anesthetic and a small amount of bone marrow and bone is withdrawn through a large needle.

      If you are found to be eligible to take part in the study, you will receive GM-CSF thorough a
      needle under your skin on Day 1. Each study cycle is about 4 weeks, but may be longer
      depending on side effects or leukemia response.

      You will receive rituximab through a needle in your vein on Day 2. The first infusion may
      take up to 8 hours. For every dose of rituximab after that, the infusion may take 2-4 hours.
      The length of the infusion time depends on whether you have any reactions to the infusion.
      The dose level of rituximab may be increased for Cycles 2-6 as well. The drugs Tylenol
      (acetaminophen) and Benadryl (diphenhydramine hydrochloride) will be given before each dose
      of rituximab. This will be done to decrease the risk of side effects. If side effects do
      occur during rituximab treatment, the drug may have to be stopped until the side effects go
      away and then restarted, so your time in the outpatient area may be longer if that occurs.

      On Days 3-5 of the first treatment cycle, fludarabine and cyclophosphamide will be given
      through a needle in your vein. Each infusion will take about 30 minutes. After the first
      treatment cycle, fludarabine and cyclophosphamide will be given on Days 2, 3, and 4 for every
      cycle after that.

      During each cycle, the day after you receive fludarabine and cyclophosphamide, you will begin
      to receive GM-CSF. You will receive the drug for 1 week or until your white cell count has
      returned to an acceptable level.

      Cycle 1 will be given at M.D. Anderson's outpatient clinic. In some cases, Cycle 1 may be
      given in the inpatient area. The other 5 cycles can be given either at M.D. Anderson or at
      another location.

      With the exception of rituximab, the same doses of all other drugs will be used throughout
      the study unless side effects become severe. In that case, the dose may be lowered, or the
      treatment may be stopped.

      During each cycle, blood (about 1 tablespoon) will be drawn once every 1-2 weeks for routine
      tests.

      You will have a bone marrow biopsy performed at the end of Cycles 3 and 6 to check the status
      of the disease.

      You may remain on study for up to 6 cycles. You will be taken off study if the disease gets
      worse or if intolerable side effects occur.

      Once you are off study, blood (about 2 teaspoons) will be drawn every 6-12 months for routine
      tests.

      This is an investigational study. Fludarabine, cyclophosphamide, rituximab, and GM-CSF are
      all FDA approved and commercially available. However, their use in this study and in this
      combination is considered investigational. Up to 60 patients will take part in the study. All
      will be enrolled at M.D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Overall Response Rate (ORR) at 6 Months Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions.</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <description>Complete Remission:Normal exam/No symptoms; Absolute lymphocyte count (ALC)&lt;/=4x10^9/L, Hb&gt;11 g/dL, absolute neutrophil count (ANC)&gt;/=1.5x109/L, &amp; platelet count&gt;100x109/L. Bone marrow:&lt;30% lymphocytes aspirate no biopsy evidence disease; Disappearance palpable lymph nodes/spleen/liver, no new lesions. Partial Remission:ALC reduced 50%,either Hb&gt;11 g/dL or 50% improvement (imp.) in deviation, or ANC&gt;/=1.5x109/L or 50% imp., or platelet&gt;100x109/L or 50% imp. in deviation from normal. Reduced 50% palpable lymph nodes/spleen/liver no new lesions. Nodular Partial Response:ALC&lt;/=4x109/L + Hb&gt;11 g/dL, ANC&gt;/=1.5x109/L &amp; platelet count&gt;100x109/L; &lt;30% lymphocytes - bone marrow biopsy aspirate + lymphoid nodules;No palpable lymph nodes/spleen/liver tumors without new lesions. Progressive Disease:50% increase (incr.) ALC&gt;10x109/L twice; tumor lesion incr. 50% over entry or responder size at time max regression &amp;/or appearance new malignant disease; Reappearance bone marrow disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Overall Response Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions.</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <description>Complete Remission:Normal exam/No symptoms; Absolute lymphocyte count (ALC)&lt;/=4x10^9/L, Hb&gt;11 g/dL, absolute neutrophil count (ANC)&gt;/=1.5x109/L, &amp; platelet count&gt;100x109/L. Bone marrow:&lt;30% lymphocytes aspirate no biopsy evidence disease; Disappearance palpable lymph nodes/spleen/liver, no new lesions. Partial Remission:ALC reduced 50%,either Hb&gt;11 g/dL or 50% improvement (imp.) in deviation, or ANC&gt;/=1.5x109/L or 50% imp., or platelet&gt;100x109/L or 50% imp. in deviation from normal. Reduced 50% palpable lymph nodes/spleen/liver no new lesions. Nodular Partial Response:ALC&lt;/=4x109/L + Hb&gt;11 g/dL, ANC&gt;/=1.5x109/L &amp; platelet count&gt;100x109/L; &lt;30% lymphocytes - bone marrow biopsy aspirate + lymphoid nodules;No palpable lymph nodes/spleen/liver tumors without new lesions. Progressive Disease:50% increase (incr.) ALC&gt;10x109/L twice; tumor lesion incr. 50% over entry or responder size at time max regression &amp;/or appearance new malignant disease; Reappearance bone marrow disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Progression-free</measure>
    <time_frame>6 months or until disease progression if earlier</time_frame>
    <description>Participants progression free as measured at six months following start of treatment. Criteria for Progressive Disease (PD): Peripheral blood: 50% increase in ALC with a level &gt; 10 x 109/L on at least 2 occasions 2 weeks apart. Tumor: An increase of a lesion by 50% over the size present at entry on study or for patients who respond, the size at the time of maximum regression and/or the appearance of new areas of malignant disease. Reappearance of bone marrow disease. A deterioration in performance status or increasing symptoms do not constitute disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>FCR + Sargramostim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Course 1: 250 mg/m^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m^2 by vein over 5-30 minutes on Days 1 - 3</description>
    <arm_group_label>FCR + Sargramostim</arm_group_label>
    <other_name>cytoxan</other_name>
    <other_name>neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Course 1: 25 mg/m^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m^2 by vein over 5-30 minutes on Days 1 - 3</description>
    <arm_group_label>FCR + Sargramostim</arm_group_label>
    <other_name>Fludarabine monophosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>Course 1: 250 mcg/m^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m^2 SQ on Days -1 and Days 4 - 10</description>
    <arm_group_label>FCR + Sargramostim</arm_group_label>
    <other_name>GM-CSF</other_name>
    <other_name>Leukine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Course 1: 375 mg/m^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m^2 by vein over 2-6 Hours on Day 1</description>
    <arm_group_label>FCR + Sargramostim</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Untreated CLL, CLL/PLL, or SLL (small lymphocytic lymphoma) with indication for
             therapy. Indications for therapy include at least one of the following: (1) one or
             more disease-related symptoms [fever, night sweats, weight loss &gt; 10% in prior 6
             months, pronounced fatigue]; (2) advanced stage disease (Rai stage &gt;/= 3 or Binet
             stage C); (3) autoimmune anemia and/or thrombocytopenia that is unresponsive to other
             therapies; (4) massive or progressive hepatomegaly and/or splenomegaly and/or
             lymphadenopathy; (5) recurrent infections; (6) rapid lymphocyte doubling time of &lt; 6
             months.

          -  Patients who have been treated with not more than one regimen of immunotherapy (e.g.
             rituximab, alemtuzumab, rituximab plus alemtuzumab) for a diagnosis of CLL, CLL/PLL,
             or SLL (small lymphocytic lymphoma).

          -  Beta-2-microglobulin &lt;/= 4 mg/dL.

          -  Adequate liver function (total bilirubin &lt;/= 2.5 mg/dL, serum glutamate pyruvate
             transaminase (SGPT) &lt;/=4 x ULN) and renal function (serum creatinine &lt;/= 2.0 mg/dL
             and/or creatinine clearance &lt; 30 mL/hour). Patients with renal or liver dysfunction
             due to suspected organ infiltration by lymphocytes may be eligible after discussion
             with the Principal Investigator, but upper limits for creatinine even under these
             circumstances must be creatinine &lt; 3mg/dL and bilirubin &lt; 6 mg/dL. Patients with
             Gilbert's syndrome may be entered on study with bilirubin levels &lt;/= 4 mg/dL.

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt;/= 2.

          -  Signed informed consent in keeping with the policies of the hospital.

          -  Male and female patients who are fertile agree to use an effective barrier method of
             birth control (ie, latex condom, diaphragm, cervical cap, etc) to avoid pregnancy.
             Female patients of childbearing potential (non-childbearing is defined as &gt;/= 1 year
             after menses cease and/or surgically sterilized) need a negative serum or urine
             pregnancy test within 2 days of study enrollment..

        Exclusion Criteria:

          -  Active hepatitis B (at least one of the following markers positive: HBsAg, hepatitis B
             e antigen (HBeAg), immunoglobulin M (IgM) anti-HBc, hepatitis B virus (HBV) DNA).

          -  Concurrent chemotherapy or immunotherapy.

          -  Pregnant patients.

          -  History of HIV

          -  Symptomatic central nervous system (CNS) disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra Ferrajoli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2006</study_first_submitted>
  <study_first_submitted_qc>September 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2006</study_first_posted>
  <results_first_submitted>July 20, 2015</results_first_submitted>
  <results_first_submitted_qc>July 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 14, 2015</results_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Sargramostim</keyword>
  <keyword>Rituximab</keyword>
  <keyword>GM-CSF</keyword>
  <keyword>FCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: September 20, 2006 to June 5, 2008. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>FCR + Sargramostim</title>
          <description>Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FCR + Sargramostim</title>
          <description>Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="35" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant Overall Response Rate (ORR) at 6 Months Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions.</title>
        <description>Complete Remission:Normal exam/No symptoms; Absolute lymphocyte count (ALC)&lt;/=4x10^9/L, Hb&gt;11 g/dL, absolute neutrophil count (ANC)&gt;/=1.5x109/L, &amp; platelet count&gt;100x109/L. Bone marrow:&lt;30% lymphocytes aspirate no biopsy evidence disease; Disappearance palpable lymph nodes/spleen/liver, no new lesions. Partial Remission:ALC reduced 50%,either Hb&gt;11 g/dL or 50% improvement (imp.) in deviation, or ANC&gt;/=1.5x109/L or 50% imp., or platelet&gt;100x109/L or 50% imp. in deviation from normal. Reduced 50% palpable lymph nodes/spleen/liver no new lesions. Nodular Partial Response:ALC&lt;/=4x109/L + Hb&gt;11 g/dL, ANC&gt;/=1.5x109/L &amp; platelet count&gt;100x109/L; &lt;30% lymphocytes - bone marrow biopsy aspirate + lymphoid nodules;No palpable lymph nodes/spleen/liver tumors without new lesions. Progressive Disease:50% increase (incr.) ALC&gt;10x109/L twice; tumor lesion incr. 50% over entry or responder size at time max regression &amp;/or appearance new malignant disease; Reappearance bone marrow disease.</description>
        <time_frame>Baseline to 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FCR + Sargramostim</title>
            <description>Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Overall Response Rate (ORR) at 6 Months Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions.</title>
          <description>Complete Remission:Normal exam/No symptoms; Absolute lymphocyte count (ALC)&lt;/=4x10^9/L, Hb&gt;11 g/dL, absolute neutrophil count (ANC)&gt;/=1.5x109/L, &amp; platelet count&gt;100x109/L. Bone marrow:&lt;30% lymphocytes aspirate no biopsy evidence disease; Disappearance palpable lymph nodes/spleen/liver, no new lesions. Partial Remission:ALC reduced 50%,either Hb&gt;11 g/dL or 50% improvement (imp.) in deviation, or ANC&gt;/=1.5x109/L or 50% imp., or platelet&gt;100x109/L or 50% imp. in deviation from normal. Reduced 50% palpable lymph nodes/spleen/liver no new lesions. Nodular Partial Response:ALC&lt;/=4x109/L + Hb&gt;11 g/dL, ANC&gt;/=1.5x109/L &amp; platelet count&gt;100x109/L; &lt;30% lymphocytes - bone marrow biopsy aspirate + lymphoid nodules;No palpable lymph nodes/spleen/liver tumors without new lesions. Progressive Disease:50% increase (incr.) ALC&gt;10x109/L twice; tumor lesion incr. 50% over entry or responder size at time max regression &amp;/or appearance new malignant disease; Reappearance bone marrow disease.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Progression-free</title>
        <description>Participants progression free as measured at six months following start of treatment. Criteria for Progressive Disease (PD): Peripheral blood: 50% increase in ALC with a level &gt; 10 x 109/L on at least 2 occasions 2 weeks apart. Tumor: An increase of a lesion by 50% over the size present at entry on study or for patients who respond, the size at the time of maximum regression and/or the appearance of new areas of malignant disease. Reappearance of bone marrow disease. A deterioration in performance status or increasing symptoms do not constitute disease progression.</description>
        <time_frame>6 months or until disease progression if earlier</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FCR + Sargramostim</title>
            <description>Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Progression-free</title>
          <description>Participants progression free as measured at six months following start of treatment. Criteria for Progressive Disease (PD): Peripheral blood: 50% increase in ALC with a level &gt; 10 x 109/L on at least 2 occasions 2 weeks apart. Tumor: An increase of a lesion by 50% over the size present at entry on study or for patients who respond, the size at the time of maximum regression and/or the appearance of new areas of malignant disease. Reappearance of bone marrow disease. A deterioration in performance status or increasing symptoms do not constitute disease progression.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Overall Response Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions.</title>
        <description>Complete Remission:Normal exam/No symptoms; Absolute lymphocyte count (ALC)&lt;/=4x10^9/L, Hb&gt;11 g/dL, absolute neutrophil count (ANC)&gt;/=1.5x109/L, &amp; platelet count&gt;100x109/L. Bone marrow:&lt;30% lymphocytes aspirate no biopsy evidence disease; Disappearance palpable lymph nodes/spleen/liver, no new lesions. Partial Remission:ALC reduced 50%,either Hb&gt;11 g/dL or 50% improvement (imp.) in deviation, or ANC&gt;/=1.5x109/L or 50% imp., or platelet&gt;100x109/L or 50% imp. in deviation from normal. Reduced 50% palpable lymph nodes/spleen/liver no new lesions. Nodular Partial Response:ALC&lt;/=4x109/L + Hb&gt;11 g/dL, ANC&gt;/=1.5x109/L &amp; platelet count&gt;100x109/L; &lt;30% lymphocytes - bone marrow biopsy aspirate + lymphoid nodules;No palpable lymph nodes/spleen/liver tumors without new lesions. Progressive Disease:50% increase (incr.) ALC&gt;10x109/L twice; tumor lesion incr. 50% over entry or responder size at time max regression &amp;/or appearance new malignant disease; Reappearance bone marrow disease.</description>
        <time_frame>Baseline to 6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FCR + Sargramostim</title>
            <description>Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Response Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions.</title>
          <description>Complete Remission:Normal exam/No symptoms; Absolute lymphocyte count (ALC)&lt;/=4x10^9/L, Hb&gt;11 g/dL, absolute neutrophil count (ANC)&gt;/=1.5x109/L, &amp; platelet count&gt;100x109/L. Bone marrow:&lt;30% lymphocytes aspirate no biopsy evidence disease; Disappearance palpable lymph nodes/spleen/liver, no new lesions. Partial Remission:ALC reduced 50%,either Hb&gt;11 g/dL or 50% improvement (imp.) in deviation, or ANC&gt;/=1.5x109/L or 50% imp., or platelet&gt;100x109/L or 50% imp. in deviation from normal. Reduced 50% palpable lymph nodes/spleen/liver no new lesions. Nodular Partial Response:ALC&lt;/=4x109/L + Hb&gt;11 g/dL, ANC&gt;/=1.5x109/L &amp; platelet count&gt;100x109/L; &lt;30% lymphocytes - bone marrow biopsy aspirate + lymphoid nodules;No palpable lymph nodes/spleen/liver tumors without new lesions. Progressive Disease:50% increase (incr.) ALC&gt;10x109/L twice; tumor lesion incr. 50% over entry or responder size at time max regression &amp;/or appearance new malignant disease; Reappearance bone marrow disease.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nodular Partial Response (nPR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event collection through total of 6 courses administered, courses are 28 to 42 days (+/- 7 days) depending on recovery of peripheral blood counts and assessments for toxicities after 3 and 6 courses, up to 252 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FCR + Sargramostim</title>
          <description>Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>FEVER OF UNKNOWN ORIGIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>SECONDARY MALIGNANCY DUCTAL CARCINOMA IN SITU RIGHT BREAST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>SECONDARY MALIGNANCY MDS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>SECONDARY MALIGNANCY SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ENCEPHALOATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain/erythema at injection site</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alessandra Ferrajoli, MD/Professor, Leukemia</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

